Although several clinical trials evaluating the effectiveness of Hsp90 inhibitors in lung cancer treatment are ongoing58, the main issues with Hsp90 inhibitors are undesirable side effects, poor water solubility, and toxicity1. This evidence concerns the gene HSP90AA1 and lung cancer.